The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical ...

HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...

SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...

SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") today announces highlights and new milestones reached during the 2024 calendar year.  The company remains committed to pioneering ...

By Steve Stricker Columnist Dr. Mark Campbell, Autum, Derek, Dorothy (Oxford Stern Cardiovascular Clinic Staff), Vallery, Carlen, Katlan, Madison (In-room preparation and monitoring), Dr. Mark, Derek, ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

A new advisory from the American Heart Association strongly endorses endovascular treatment for patients with large core ...